✦ LIBER ✦

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

✍ Scribed by Coleman, Robert; Cameron, David; Dodwell, David; Bell, Richard; Wilson, Caroline; Rathbone, Emma; Keane, Maccon; Gil, Miguel; Burkinshaw, Roger; Grieve, Robert; Barrett-Lee, Peter; Ritchie, Diana; Liversedge, Victoria; Hinsley, Samantha; Marshall, Helen

Book ID: 125823647
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 537 KB
Volume: 15
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(14)70302-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety of zoledronic acid and incidence

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer

✍ R. Coleman; E. Woodward; J. Brown; D. Cameron; R. Bell; D. Dodwell; M. Keane; M. 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 339 KB

Safety of zoledronic acid and incidence

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE–BIG 01–04) for women with stage II/III breast cancer

✍ R.E. Coleman; E.J. Woodward*; J.E. Brown; D. Cameron; R. Bell; D. Dodwell; M. Ke 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Adjuvant chemotherapy and timing of tamo

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

✍ Kathy S Albain; William E Barlow; Peter M Ravdin; William B Farrar; Gary V Burto 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 145 KB

Efficacy and safety of 12-weekly versus

Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial

✍ Amadori, Dino; Aglietta, Massimo; Alessi, Barbara; Gianni, Lorenzo; Ibrahim, Ton 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 265 KB

Subcutaneous versus intravenous administ

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

✍ Gustavo Ismael; Roberto Hegg; Susanne Muehlbauer; Dominik Heinzmann; Bert Lum; S 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 245 KB